Monday, August 17, 2009

Amgen said Vectibix improved survival as second-line treatment for ... - Los Angeles Times


Amgen said Vectibix improved survival as second-line treatment for ...
Los Angeles Times
Shares of Amgen rose 5 cents to $59.89 in after-hours trading after falling $1.01 to close at $59.84 during the lawful trading session.

and more »

No comments:

Post a Comment